Skip to main content
SpringerLink
Log in

Das sogenannte "Chemobrain"

Kognitive Dysfunktion bei Krebskranken - ein oft unterbewertetes Symptom

  • Supportivtherapie
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur:

  1. Lange M et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925-40

  2. Wefel JS et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-8

  3. Lycke M et al. Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment. Psychooncology. 2017;26(5):632-9

  4. Janelsins MC et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102-13

  5. Ganz PA et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791-801

  6. Paquet L et al. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors. Psychooncology. 2018;27(1):171-77

  7. Allen DH, Loughan AR. Impact of Cognitive Impairment in Patients with Gliomas. Semin Oncol Nurs. 2018;34(5):528-46

  8. Ahles TA, Root JC. Cognitive Effects of Cancer and Cancer Treatments. Annu Rev Clin Psychol. 2018;14:425-51

  9. Hardy SJ et al. Cognitive Changes in Cancer Survivors. Am Soc Clin Oncol Educ Book. 2018;38:795-806

  10. Koppelmans V et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080-6

  11. Hermelink K et al. Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. J Natl Cancer Inst. 2017;109(10):10.1093/jnci/djx057

  12. McGinty HL et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271-80

  13. Ahles TA et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434-40

  14. Schilder CM et al. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010;76(2):133-41

  15. Hermelink K et al. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008;113(9):2431-9

  16. Ganz PA et al. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol. 2014;32(31):3559-67

  17. Bender CM et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015;121(15):2627-3

  18. Joly F et al. Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer. Eur Urol Focus. 2016;2(6):642-9

  19. McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy. 2017;9(11):929-41

  20. Lawrie TA et al. Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Rev. 2019;8(8):CD013047

  21. Byeongsang Oh 1 et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer. 2012;20(6):1235-42

  22. Jalali R et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol. 2017;3(10):1368-76

  23. Brown PD et al; for NRG Oncology. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019-29

  24. Grosu AL et al. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG). BMC Cancer. 2020;20(1):532

  25. https://nccn.gov zuletzt abgerufen: 26.7.2023

  26. Allen DH et al. Assessment and Management of Cancer- and Cancer Treatment-Related Cognitive Impairment. Nurse Pract. 2018;14(4):217-24

  27. Wefel JS et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-8

  28. Rick O, König V. Krebsbedingte kognitive Dysfunktion. Cancer-related cognitive dysfunction. Die Onkologie. 2022; 28(9)

  29. Scherwath A et al. Psychometric evaluation of a neuropsychological test battery measuring cognitive dysfunction in cancer patients--recommendations for a screening tool. Fortschr Neurol Psychiatr. 2008;76(10):583-93

  30. Schmitz KH et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409-26

  31. Fardell JE, et al. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity.Psychopharmacology (Berl). 2012;220(1):183-93

  32. Hines S et al. The effectiveness of psychosocial interventions for cognitive dysfunction in cancer patients who have received chemotherapy: a systematic review. Worldviews Evid Based Nurs. 2014;11(3):187-93

  33. Bray VJ et al. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol. 2017;35(2):217-25

  34. Kesler S et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13(4):299-306

  35. Fernandes HA et al. Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support Care Cancer. 2019;27(9):3253-79

  36. Karschnia P et al. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20(2):e92-e102

  37. Fan HG et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology. 2009;18(2):156-61

Download references

Author information

Authors and Affiliations

  1. Asklepios Nordseeklinik Westerland GmbH, Norderstrasse 81, Sylt / OT Westerland, Deutschland

    Georgia Schilling

Authors
  1. Georgia Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schilling, G. Das sogenannte "Chemobrain". Im Fokus Onkologie 26, 52–57 (2023). https://doi.org/10.1007/s15015-023-3200-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-023-3200-8

Search

Navigation